MX7563E - Procedimiento para preparar un complejo inmunogeno que contiene proteinas antigenicas y peptidos - Google Patents

Procedimiento para preparar un complejo inmunogeno que contiene proteinas antigenicas y peptidos

Info

Publication number
MX7563E
MX7563E MX8310844U MX1084483U MX7563E MX 7563 E MX7563 E MX 7563E MX 8310844 U MX8310844 U MX 8310844U MX 1084483 U MX1084483 U MX 1084483U MX 7563 E MX7563 E MX 7563E
Authority
MX
Mexico
Prior art keywords
peptides
preparing
procedure
complex containing
antigenic proteins
Prior art date
Application number
MX8310844U
Other languages
English (en)
Inventor
Bror Morei
Original Assignee
Bror Morei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morei filed Critical Bror Morei
Publication of MX7563E publication Critical patent/MX7563E/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX8310844U 1982-10-18 1983-10-18 Procedimiento para preparar un complejo inmunogeno que contiene proteinas antigenicas y peptidos MX7563E (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8205892A SE8205892D0 (sv) 1982-10-18 1982-10-18 Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Publications (1)

Publication Number Publication Date
MX7563E true MX7563E (es) 1989-10-17

Family

ID=20348235

Family Applications (1)

Application Number Title Priority Date Filing Date
MX8310844U MX7563E (es) 1982-10-18 1983-10-18 Procedimiento para preparar un complejo inmunogeno que contiene proteinas antigenicas y peptidos

Country Status (18)

Country Link
US (2) US4578269A (es)
EP (1) EP0109942B1 (es)
JP (1) JPH07112983B2 (es)
AR (1) AR243080A1 (es)
AT (1) ATE61228T1 (es)
AU (1) AU558258B2 (es)
CA (1) CA1243954A (es)
DE (2) DE3382190D1 (es)
DK (1) DK162057C (es)
ES (1) ES8503951A1 (es)
FI (1) FI80600C (es)
IE (1) IE57025B1 (es)
MX (1) MX7563E (es)
NO (1) NO163668C (es)
NZ (1) NZ205925A (es)
PT (1) PT77515B (es)
SE (1) SE8205892D0 (es)
ZA (1) ZA837603B (es)

Families Citing this family (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804624A (en) * 1982-05-21 1989-02-14 The University Of Tennessee Research Corporation Passive agglutination assay for pseudorabies antibody
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
SE8402861L (sv) * 1984-05-28 1985-11-29 Stefan Svenson Rening av biologiskt material
NL8403195A (nl) * 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
ES2039229T3 (es) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
ZA872203B (en) * 1986-04-28 1988-02-24 New York Blood Center Inc Complex immunogen containing synthetic peptides
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
DE3853079T3 (de) * 1987-12-04 2000-11-09 The Liposome Co.,Inc. Liposome hoher stabilität und verfahren zur herstellung und verwendung.
AU3048689A (en) * 1988-01-13 1989-08-11 University Of North Carolina At Chapel Hill, The Immunogenic peptides
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
DK199588D0 (da) * 1988-04-12 1988-04-12 Nordisk Droge & Kemikalie Vaccine
US5885589A (en) * 1988-04-12 1999-03-23 Intervet International B.V. Pasteurella vaccine
EP0372056A4 (en) * 1988-05-04 1991-05-15 Dana Farber Cancer Institute Protein micelles
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
GB8818415D0 (en) * 1988-08-03 1988-09-07 Animal Health Inst Vaccine
US6291228B1 (en) * 1988-08-03 2001-09-18 Vericore Limited Vaccine
JPH0292996A (ja) * 1988-09-30 1990-04-03 Bror Morein アジュバントおよび脂質を含む複合体
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
ATE148348T1 (de) * 1989-09-15 1997-02-15 Tanox Biosystems Inc Behandlung von einer autoimmun-krankheit
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
DE4220653A1 (de) * 1992-06-26 1994-01-13 Boehringer Mannheim Gmbh Verfahren und Mittel zum Nachweis eines Analyten enthaltend glykosidische Tenside
EP0604727A1 (en) * 1992-12-31 1994-07-06 American Cyanamid Company Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
PT716697E (pt) * 1993-09-03 2003-08-29 Univ Mcgill Genes e proteinas de leishmania expressos diferencialmente
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996015807A1 (en) * 1994-11-21 1996-05-30 Scofield Virginia L Sperm as vaccine vectors
DE69636935T2 (de) * 1995-01-27 2007-11-22 Genencor International, Inc., Palo Alto Verfahren zur extraktion von enzymen unter verwendung von tensiden
WO1996040234A1 (en) 1995-06-07 1996-12-19 Pfizer Inc. In ovo vaccination against coccidiosis
DK0831896T3 (da) * 1995-06-07 2001-09-03 Pfizer In ovo-vaccination mod coccidiosis
ZA97452B (en) 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
GB9618119D0 (en) * 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
ZA9710606B (en) * 1996-12-05 1998-06-12 Akzo Nobel Nv Non-virulent Mycoplasma synoviae vaccine thereof.
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6627205B2 (en) 1997-12-01 2003-09-30 Pfizer Incorporated Ovo vaccination against coccidiosis
US6495140B1 (en) 1998-01-12 2002-12-17 Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Process for the isolation, recovery and purification of non-polar extractives
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
US6984378B1 (en) 1999-02-26 2006-01-10 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
JP4892134B2 (ja) 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
AU764969B2 (en) 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
DE60036952T2 (de) * 1999-09-24 2008-08-07 Glaxosmithkline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
NZ518999A (en) * 1999-11-19 2002-12-20 Csl Ltd Vaccine compositions
CA2402252A1 (en) 2000-03-17 2001-09-27 Pharmacia & Upjohn Company Salmonella vaccine materials and methods
AU2001251370A1 (en) 2000-04-06 2001-10-23 Pharmacia And Upjohn Company Antimicrobial methods and materials
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
ES2377077T3 (es) 2000-10-18 2012-03-22 Glaxosmithkline Biologicals S.A. Vacunas que comprenden al antígeno MAGE unido a un fragmento de proteína D
MXPA03003408A (es) * 2000-10-18 2005-06-30 Glaxosmithkline Biolog Sa Vacunas.
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
JP2004528321A (ja) 2001-04-04 2004-09-16 ノルディック ワクチン テクノロジー アクティーゼルスカブ ステロールおよびサポニンを含むポリヌクレオチド結合複合体
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
KR20040021678A (ko) 2001-08-30 2004-03-10 엠브렉스, 인코포레이티드 난포낭을 생산하기 위한 개선된 방법
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1532253B1 (en) 2002-08-12 2014-04-30 Intervet International BV Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
SI1549338T1 (sl) 2002-10-11 2011-04-29 Novartis Vaccines & Diagnostic Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi
US7125425B2 (en) * 2002-10-21 2006-10-24 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
DE60335742D1 (de) 2002-11-20 2011-02-24 Bestewil Holding Bv Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
TWI329130B (en) 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1961426B1 (en) 2003-10-02 2011-04-27 Novartis Vaccines and Diagnostics S.r.l. Combined meningitis vaccines
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
CA2567446C (en) 2004-05-21 2018-01-02 Chiron Corporation Alphavirus vectors for respiratory pathogen vaccines
DE602005025342D1 (de) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006078213A1 (en) 2005-01-20 2006-07-27 Isconova Ab Vaccine composition comprisinga fibronectin binding protein or a fibronectin binding peptide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
US8758764B2 (en) 2005-02-18 2014-06-24 Novartis Vaccines And Diagnostics Srl Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
AU2006257383A1 (en) 2005-06-16 2006-12-21 Universiteit Gent Vaccines for immunization against Helicobacter
EP1912665B1 (en) 2005-07-28 2011-01-26 Pfizer Products Inc. Vaccine against feline calicivirus (fcv) comprising a fcv capsid protein or an isolated fcv capsid protein comprising protein sequence seq id no: 13 or protein sequences having at least 95% identity thereto.
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
EP2452693A3 (en) 2005-10-07 2012-06-06 Pfizer Products Inc. Vaccines and methods to treat canine influenza
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
PT2368572T (pt) 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AR058707A1 (es) 2005-12-22 2008-02-20 Glaxosmithkline Biolog Sa Vacuna, procedimiento para fabricarla y su uso
US20110027314A1 (en) 2006-01-27 2011-02-03 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Influenza Vaccines Containing Hemagglutinin and Matrix Proteins
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
BRPI0710210A2 (pt) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
MX2008016280A (es) 2006-06-29 2009-03-26 Novartis Ag Polipeptidos a partir de neisseria meningitidis.
WO2008009650A2 (en) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
ES2694805T7 (es) 2006-09-11 2021-10-21 Seqirus Uk Ltd Fabricación de vacunas contra virus de la gripe sin usar huevos
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
MX2009007087A (es) 2006-12-27 2009-08-12 Pfizer Prod Inc Metodos para la administracion de vacunas.
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
MX2009012777A (es) 2007-05-25 2009-12-16 Novartis Ag Antigenos pilus de streptococcus pneumoniae.
EP2167121B1 (en) 2007-06-26 2015-09-02 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
RU2471497C2 (ru) 2007-09-12 2013-01-10 Новартис Аг Мутантные антигены gas57 и антитела против gas57
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008352942B2 (en) 2007-12-19 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN101977926B (zh) 2007-12-21 2014-10-08 诺华股份有限公司 链球菌溶血素o的突变形式
EP4219566A3 (en) 2007-12-24 2023-09-06 ID Biomedical Corporation of Quebec Recombinant rsv antigens
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
EP3459563A1 (en) 2008-03-18 2019-03-27 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
WO2010094663A1 (en) 2009-02-17 2010-08-26 Glaxosmithkline Biologicals S.A. Inactivated dengue virus vaccine with aluminium-free adjuvant
EP3549602A1 (en) 2009-03-06 2019-10-09 GlaxoSmithKline Biologicals S.A. Chlamydia antigens
US8679505B2 (en) 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
CN102802665B (zh) 2009-06-15 2015-11-25 新加坡国立大学 流感疫苗、组合物及使用方法
US9492531B2 (en) 2009-06-24 2016-11-15 Glaxosmithkline Biologicals Sa Recombinant RSV vaccines
EA201270062A1 (ru) 2009-06-24 2013-02-28 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Вакцина
AU2010269148A1 (en) * 2009-07-10 2012-01-19 Isconova Ab New composition
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
DK2464658T3 (en) 2009-07-16 2014-12-15 Novartis Ag Detoxified escherichia coli immunogens
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012009309B1 (pt) 2009-10-19 2021-10-05 Intervet International B.V Vacina combinada, uso de células de microrganismos,método para a preparação de uma vacina combinada, e, kit de partes
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
US20130251719A1 (en) 2009-10-22 2013-09-26 Tiergesundheitsdienst Bayern E.V. Bone marrow aplasia with haemorrhagic disease in calves caused by novel pathogen
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
EP2552480A1 (en) 2010-03-26 2013-02-06 GlaxoSmithKline Biologicals S.A. Hiv vaccine
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
CA2796178C (en) 2010-04-21 2021-02-16 Pharmaq As Nucleic acid sequences of fish cardiomyopathy syndrome virus and the use thereof
CN107641151B (zh) 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
KR102058307B1 (ko) * 2010-06-24 2019-12-20 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
NZ606087A (en) 2010-07-23 2014-06-27 Isconova Ab Influenza vaccine
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
KR20130139953A (ko) 2010-09-27 2013-12-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012059593A1 (en) 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
CA2817933A1 (en) 2010-11-15 2012-05-24 Pharmaq As New salmon calicivirus isolate
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012076668A1 (en) 2010-12-08 2012-06-14 Neovacs Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
BR112013016694A2 (pt) 2010-12-29 2018-05-22 Intervet Int Bv ácido nucleico isolado, microrganismo carregador recombinante vivo. anticorpo monocolonal, vacina para caninos contra babesiose, método para a preparação de vacina, uso de polipeptídeo ou fragmento imunogêncio do mesmo, e, kit de teste de diagnóstico
US9139618B2 (en) 2010-12-29 2015-09-22 Intervet Inc. Salmonid alphavirus protein E2
EP2662389B1 (en) 2011-01-07 2019-03-13 Toagosei Co., Ltd Method for preparing antigen to obtain antihydrophobic peptide antibody
DK2667892T3 (da) 2011-01-26 2019-05-13 Glaxosmithkline Biologicals Sa RSV-vaccineringsprogram
US20140086954A1 (en) 2011-03-31 2014-03-27 Chu De Toulouse Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
BR112013025892B1 (pt) 2011-04-07 2021-01-19 Neovacs produto imunogênico, forma de dosagem unitária, dispositivo médico e kit relacionados a ifna
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
KR20200040899A (ko) 2011-05-13 2020-04-20 조에티스 서비시즈 엘엘씨 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물
JP2014519819A (ja) 2011-05-13 2014-08-21 ノバルティス アーゲー 融合前ｒｓｖｆ抗原
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
AR087811A1 (es) 2011-09-08 2014-04-16 Umc Utrecht Holding Bv Vacuna contra el staphylococcus aureus
EP2755683B1 (en) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Methods for making saccharide-protein glycoconjugates
EP3311827B1 (en) 2011-10-03 2023-01-04 Canqura Oncology Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
MY188083A (en) 2011-11-23 2021-11-16 In3Bio Ltd Recombinant proteins and their therapeutic uses
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN104363892A (zh) 2012-02-07 2015-02-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
RU2015106742A (ru) 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
CN104602702B (zh) 2012-09-18 2021-08-27 葛兰素史密丝克莱恩生物有限公司 外膜囊泡
SG10201702685WA (en) 2012-10-03 2017-04-27 Glaxosmithkline Biolog Sa Immunogenic composition
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
CA2892688A1 (en) 2012-11-30 2014-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
ES2924914T3 (es) 2013-03-15 2022-10-11 Glaxosmithkline Biologicals Sa Vacuna contra rinovirus humano
CA2904506A1 (en) 2013-03-15 2014-09-18 Bioven 3 Limited Self-assembling synthetic proteins
NZ712410A (en) 2013-03-26 2020-01-31 The Pirbright Inst Stabilised fmdv capsids
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
EP3552621A3 (en) 2013-10-11 2020-01-08 Servizo Galego De Saúde (Sergas) Live attenuated vaccines
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US20160331829A1 (en) 2013-12-16 2016-11-17 Zoetis Services Llc Hendra and nipah virus g glycoprotein immunogenic compositions
KR20220100041A (ko) 2013-12-31 2022-07-14 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 단일 바이알 백신 제형
EP3639850A1 (en) 2014-03-26 2020-04-22 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens
EP3134114A4 (en) 2014-04-24 2018-03-14 Rhode Island Hospital Aspartate-beta -hydroxylase induces epitope-specific t cell responses in tumors
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
US9790509B2 (en) 2014-07-18 2017-10-17 Oregon Health & Science University 5′-triphosphate oligoribonucleotides
CN104250640A (zh) 2014-08-22 2014-12-31 普莱柯生物工程股份有限公司 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
MX2017002803A (es) 2014-09-03 2017-06-09 Intervet Int Bv Coronavirus bovino atenuado y vacunas relacionadas.
CN106794242B (zh) 2014-10-03 2021-11-30 英特维特国际股份有限公司 针对禽类呼肠孤病毒的广谱疫苗
EP3613764A1 (en) 2014-10-15 2020-02-26 Xenothera Composition with reduced immunogenicity
CA2977493C (en) 2015-03-03 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
CN111560355A (zh) 2015-03-20 2020-08-21 普莱柯生物工程股份有限公司 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用
US10954492B2 (en) 2015-06-10 2021-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Processes for production and purification of nucleic acid-containing compositions
BR112018004242A2 (pt) 2015-09-03 2018-09-25 Novavax Inc composições de vacina que possuem estabilidade e imunogenicidade aumentadas
CN105770887A (zh) * 2016-03-04 2016-07-20 邓招红 一种用于hbv疫苗的佐剂及其制备方法
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
CA3033759C (en) 2016-08-17 2022-06-14 Pharmaq As Sea lice vaccine
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
CA3070034A1 (en) 2017-07-18 2019-01-24 In3Bio Ltd. Synthetic proteins and therapeutic uses thereof
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
MX2020009682A (es) 2018-03-19 2020-10-12 Novavax Inc Vacunas de nanoparticulas multivalentes contra la influenza.
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
WO2020039033A1 (en) 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
CA3144845A1 (en) 2019-06-25 2020-12-30 In3Bio Ltd. Stabilized chimeric synthetic proteins and therapeutic uses thereof
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
MX2023006320A (es) 2020-12-02 2023-06-14 Glaxosmithkline Biologicals Sa Cadena donante complementada fimh.
JP2024500935A (ja) 2020-12-23 2024-01-10 ゼノセラ 抗感染受動免疫療法における、抗体依存性マクロファージ炎症誘発性サイトカインの放出を治療及び／又は予防するためのその使用のためのブタポリクローナル抗体組成物
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023114727A1 (en) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2023225458A1 (en) 2022-05-16 2023-11-23 Zoetis Services Llc Vaccines against moritella viscosa
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4251509A (en) * 1980-01-31 1981-02-17 Wisconsin Alumni Research Foundation Dry particulate vaccine for oral administration
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
EP0056249B1 (en) * 1981-01-09 1985-06-26 New York Blood Center, Inc. Synthetic antigenic composition and process for making same
GB2093039B (en) * 1981-01-29 1984-06-06 Nat Res Dev Improvements relating to hepatitis b vaccine
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Also Published As

Publication number Publication date
ES526524A0 (es) 1985-04-01
DK162057B (da) 1991-09-09
NZ205925A (en) 1987-10-30
PT77515B (en) 1986-04-16
FI80600C (fi) 1990-07-10
DK478383A (da) 1984-04-19
JPS59186921A (ja) 1984-10-23
FI833748A (fi) 1984-04-19
IE57025B1 (en) 1992-03-25
SE8205892D0 (sv) 1982-10-18
ES8503951A1 (es) 1985-04-01
NO833769L (no) 1984-04-24
DE3382190D1 (de) 1991-04-11
FI833748A0 (fi) 1983-10-14
DE109942T1 (de) 1984-12-06
CA1243954A (en) 1988-11-01
NO163668B (no) 1990-03-26
PT77515A (en) 1983-11-01
AU558258B2 (en) 1987-01-22
US4578269A (en) 1986-03-25
EP0109942B1 (en) 1991-03-06
AU2010383A (en) 1984-05-03
FI80600B (fi) 1990-03-30
ZA837603B (en) 1984-12-24
EP0109942A3 (en) 1985-08-14
DK478383D0 (da) 1983-10-17
JPH07112983B2 (ja) 1995-12-06
US4744983A (en) 1988-05-17
DK162057C (da) 1992-02-10
AR243080A1 (es) 1993-07-30
ATE61228T1 (de) 1991-03-15
NO163668C (no) 1990-07-04
EP0109942A2 (en) 1984-05-30
IE832394L (en) 1984-04-18

Similar Documents

Publication Publication Date Title
MX7563E (es) Procedimiento para preparar un complejo inmunogeno que contiene proteinas antigenicas y peptidos
ES533105A0 (es) Un procedimiento para preparar un oligopeptidos antigenico
DK318481A (da) Syntetisk peptid specifik antigenisk determinant og fremgangsmaade til fremstilling af antigene meneraler deraf
DK550780A (da) Forfalskningssikkert dokument samt fremgangsmaade til fremstilling deraf
DK159997C (da) Polyesterholdigt filamentmateriale samt fremgangsmaade til fremstilling deraf
ES557363A0 (es) Procedimiento para preparar peptidos trifluormetilcetona-sustituidos
IT1119257B (it) Procedimento e reagente per raggi immunologici
DK307883D0 (da) Carbostyrilderivater samt fremgangsmade til fremstilling deraf
ES529961A0 (es) Procedimiento para preparar vacunas polivalentes adsorbidas y liofilizadas
NO792822L (no) Antigen-preparat og fremgangsmaate for fremstilling derav
DK93383D0 (da) Glycoproteiner samt fremgangsmade til fremstilling heraf
NO842962L (no) Fremgangsmaate for fremstilling av et polypeptid egnet for anvendelse i en vaksinasjonsprosedyre
MX161186A (es) Procedimiento para preparar peptidos
DK64183D0 (da) Farmaceutisk praeparat samt fremgangsmade til fremstilling deraf
ES543973A0 (es) Procedimiento para preparar peptidos
ES524245A0 (es) Procedimiento para obtener un polipeptido
MX7572E (es) Procedimiento para preparar proteina unicelular
MX7655E (es) Procedimiento para preparar substancias proteinicas antitumorales
DK489683D0 (da) Fremgangsmade til fremstilling af peptider
ES534800A0 (es) Procedimiento para preparar ciclopeptidos
ES522662A0 (es) Procedimiento para preparar piridil y quinolil-imidazolinonas.
NO833655L (no) Fremgangsmaate for fremstilling av antigen
DK364483A (da) 14-aminosteroid-derivater samt fremgangsmaade til fremstilling deraf
DK49686D0 (da) Antigeniske peptider
ES525085A0 (es) Procedimiento para preparar n-alil-olalquil-tionocarbamatos